{"id":40105,"date":"2025-10-31T21:06:17","date_gmt":"2025-10-31T16:06:17","guid":{"rendered":"https:\/\/menamedicalresearch.com\/news\/?p=40105"},"modified":"2025-10-31T21:21:34","modified_gmt":"2025-10-31T16:21:34","slug":"post-cytotoxic-myeloid-neoplasms-a-mena-region-study-of-clinicopathologic-genetic-profile-latency-determinants-and-prognostic-predictors","status":"publish","type":"post","link":"https:\/\/menamedicalresearch.com\/news\/cancers\/post-cytotoxic-myeloid-neoplasms-a-mena-region-study-of-clinicopathologic-genetic-profile-latency-determinants-and-prognostic-predictors\/","title":{"rendered":"Post-cytotoxic myeloid neoplasms: a MENA region study of clinicopathologic, genetic profile, latency determinants and prognostic predictors"},"content":{"rendered":"

Post-cytotoxic myeloid neoplasms (MN-PCT<\/strong>), also known as therapy-related myeloid neoplasms<\/strong> (t-MN<\/strong>), represent a heterogeneous group of hematologic malignancies that develop after a patient receives cytotoxic chemotherapy or radiotherapy for an unrelated condition.<\/p>\n

These disorders, which include therapy-related myelodysplastic syndrome (t-MDS), acute myeloid leukemia (t-AML), and myelodysplastic\/myeloproliferative neoplasms (t-MDS\/MPN) are notorious for their aggressive nature, universally poor survival, and a lack of consensus on reliable prognostic indicators.<\/strong> This complexity stems from a combination of the cytotoxic treatment effects, genetic instability, and patient-specific variables.<\/p>\n

To address the limited understanding of this entity, a 10-year retrospective, <\/strong>single-center study was conducted at the National Center for Cancer Care and Research (NCCCR) in Qatar<\/strong>. Analyzing a cohort of 42 MN-PCT patients, this research offers the first comprehensive dataset on t-MN from the Middle East and North Africa (MENA) <\/strong>region.<\/p>\n

The analysis revealed several critical findings. The most common genetic mutation was found in the TP53 gene<\/strong>, present in 28.6%<\/strong> of tested cases. Notably, the study found a high prevalence of autoimmune diseases (30.9%) as the original primary condition, a percentage higher than previously documented. A shorter latency period\u2014the time from prior therapy to MN-PCT diagnosis\u2014was significantly associated with previous exposure to alkylating agents and TP53 positivity. Patients aged 50 or younger demonstrated a longer median survival.<\/strong><\/p>\n

Researchers identified multiple factors affecting disease progression and patient outcome. \u00a0Dyserythropoiesis, Myeloperoxidase downregulation, mutated TP53, and failure to achieve clinical remission were identified as poor prognostic markers.\u00a0<\/strong>A latency period of \u2265 5 years and TP53 positivity were identified as statistically significant independent factors associated with reduced overall survival<\/strong>. P53 mutation was a common parameter that adversely impacted both MN-PCT survival and overall survival.<\/p>\n

This study significantly advances the understanding of MN-PCT in an underrepresented population. The findings underscore the importance of recognizing MN-PCT as a distinct clinical and pathological entity in future classification systems, emphasizing that adverse prognostic factors extend beyond mere genetic influences.<\/p>\n

Reference Source
\n<\/strong>Soliman, D.S., Fareed, S., Chandra, P. et al. (2025). Post-cytotoxic myeloid neoplasms: a comprehensive analysis of clinicopathologic, genetic profile, latency determinants, and potential prognostic predictors- a single centre study. Annals of Hematology<\/em>. DOI: https:\/\/doi.org\/10.1007\/s00277-025-06651-0<\/p>\n

 <\/p>\n","protected":false},"excerpt":{"rendered":"

Post-cytotoxic myeloid neoplasms (MN-PCT), also known as therapy-related myeloid neoplasms (t-MN), represent a heterogeneous group of hematologic malignancies that develop after a patient receives cytotoxic chemotherapy or radiotherapy for an unrelated condition. These disorders, which include therapy-related myelodysplastic syndrome (t-MDS), acute myeloid leukemia (t-AML), and myelodysplastic\/myeloproliferative neoplasms (t-MDS\/MPN) are notorious for their aggressive nature, universally …<\/p>\n","protected":false},"author":1,"featured_media":40107,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[39],"tags":[],"class_list":["post-40105","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cancers"],"acf":[],"aioseo_notices":[],"aioseo_head":"\n\t\t\n\t\n\t\n\t\n\t\n\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t